puyisita mesylate

Puyisita mesylate (PTS-02) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor developed by Guizhou Bailing Enterprise Group Pharmaceutical. As a Class 1.1 innovative drug in China, it is designed to treat various hematologic malignancies by inhibiting HDAC enzymes, which are involved in the epigenetic regulation of gene expression. Inhibition of these enzymes leads to increased histone acetylation, chromatin remodeling, and the induction of cell cycle arrest and apoptosis in cancer cells. Puyisita mesylate is currently being evaluated in Phase 1 and Phase 2 clinical trials for indications such as relapsed or refractory B-cell non-Hodgkin's lymphoma, multiple myeloma, and acute lymphoblastic leukemia.

Other names

puyisita普依司他PTS-02 mesylatePTS02 mesylatePTS 02 mesylate